OBJECTIVE: To assess the prevalence of mood and anxiety disorders in systemic sclerosis (SSc) patients and the association of these disorders with clinical features. METHODS: Between May 2002 and May 2004, 100 SSc patients fulfilling the American Rheumatism Association and/or Leroy & Medsger criteria were recruited: 51 were from a SSc patient association meeting, and 49 were hospitalized in an internal medicine department and recruited consecutively. Mood and anxiety disorders were assessed by use of a structured clinical interview [the Mini International Neuropsychiatric Interview (MINI)] performed by a psychiatrist and a self-reporting questionnaire [the Hospital Anxiety and Depression Scale (HADS)]. On the same day, psychiatric treatment and clinical features were recorded by a physician. RESULTS: As assessed by the MINI, 19% [95% confidence interval 12-28%] of all SSc patients were currently experiencing a major depressive episode (MDE), 56% [46-65%] had a lifetime history of MDE and 14% [8-22%] had current dysthymia. Current MDE was more prevalent among hospitalized patients than among other patients (28% versus 10%, p=0.02). Specific anxiety disorders were diagnosed in 37 [28-47] patients. Less than 50% of the patients with mood disorders received psychiatric treatment. Patients with or without current depression did not differ in clinical symptoms of SSc, except for digestive symptoms. CONCLUSION: The current and lifetime prevalence of major depression and anxiety disorders is high in SSc patients, especially during hospitalization. However, only half of such patients receive adequate psychiatric treatment. Therefore, a better assessment of psychiatric disorders in SSc patients is needed.
OBJECTIVE: To assess the prevalence of mood and anxiety disorders in systemic sclerosis (SSc) patients and the association of these disorders with clinical features. METHODS: Between May 2002 and May 2004, 100 SSc patients fulfilling the American Rheumatism Association and/or Leroy & Medsger criteria were recruited: 51 were from a SSc patient association meeting, and 49 were hospitalized in an internal medicine department and recruited consecutively. Mood and anxiety disorders were assessed by use of a structured clinical interview [the Mini International Neuropsychiatric Interview (MINI)] performed by a psychiatrist and a self-reporting questionnaire [the Hospital Anxiety and Depression Scale (HADS)]. On the same day, psychiatric treatment and clinical features were recorded by a physician. RESULTS: As assessed by the MINI, 19% [95% confidence interval 12-28%] of all SSc patients were currently experiencing a major depressive episode (MDE), 56% [46-65%] had a lifetime history of MDE and 14% [8-22%] had current dysthymia. Current MDE was more prevalent among hospitalized patients than among other patients (28% versus 10%, p=0.02). Specific anxiety disorders were diagnosed in 37 [28-47] patients. Less than 50% of the patients with mood disorders received psychiatric treatment. Patients with or without current depression did not differ in clinical symptoms of SSc, except for digestive symptoms. CONCLUSION: The current and lifetime prevalence of major depression and anxiety disorders is high in SSc patients, especially during hospitalization. However, only half of such patients receive adequate psychiatric treatment. Therefore, a better assessment of psychiatric disorders in SSc patients is needed.
Authors: Brett D Thombs; Lisa R Jewett; Shervin Assassi; Murray Baron; Susan J Bartlett; Angela Costa Maia; Ghassan El-Baalbaki; Daniel E Furst; Karen Gottesman; Jennifer A Haythornthwaite; Marie Hudson; Ann Impens; Annett Korner; Catarina Leite; Maureen D Mayes; Vanessa L Malcarne; Sarosh J Motivala; Luc Mouthon; Warren R Nielson; Diane Plante; Serge Poiraudeau; Janet L Poole; Janet Pope; Maureen Sauve; Russell J Steele; Maria E Suarez-Almazor; Suzanne Taillefer; Cornelia H van den Ende; Erin Arthurs; Marielle Bassel; Vanessa Delisle; Katherine Milette; Allison Leavens; Ilya Razykov; Dinesh Khanna Journal: Clin Exp Rheumatol Date: 2012-05-29 Impact factor: 4.473
Authors: Leticia Leon; Lydia Abasolo; Marta Redondo; Miguel Angel Perez-Nieto; Luis Rodriguez-Rodriguez; Maria Isabel Casado; Rafael Curbelo; Juan Angel Jover Journal: Rheumatol Int Date: 2013-09-27 Impact factor: 2.631
Authors: Jose-Ezequiel Martin; Shervin Assassi; Lina-Marcela Diaz-Gallo; Jasper C Broen; Carmen P Simeon; Ivan Castellvi; Esther Vicente-Rabaneda; Vicente Fonollosa; Norberto Ortego-Centeno; Miguel A González-Gay; Gerard Espinosa; Patricia Carreira; Mayte Camps; Jose M Sabio; Sandra D'alfonso; Madelon C Vonk; Alexandre E Voskuyl; Annemie J Schuerwegh; Alexander Kreuter; Torsten Witte; Gabriella Riemekasten; Nicolas Hunzelmann; Paolo Airo; Lorenzo Beretta; Raffaella Scorza; Claudio Lunardi; Jacob Van Laar; Meng May Chee; Jane Worthington; Arianne Herrick; Christopher Denton; Carmen Fonseca; Filemon K Tan; Frank Arnett; Xiaodong Zhou; John D Reveille; Olga Gorlova; Bobby P C Koeleman; Timothy R D J Radstake; Timothy Vyse; Maureen D Mayes; Marta E Alarcón-Riquelme; Javier Martin Journal: Hum Mol Genet Date: 2013-06-04 Impact factor: 6.150
Authors: Thomas Hyphantis; Konstantinos Kotsis; Niki Tsifetaki; Francis Creed; Alexandros A Drosos; André F Carvalho; Paraskevi V Voulgari Journal: Clin Rheumatol Date: 2013-01-18 Impact factor: 2.980
Authors: Angela Del Rosso; Svetlana Mikhaylova; Marco Baccini; Ilaria Lupi; Marco Matucci Cerinic; Susanna Maddali Bongi Journal: Biomed Res Int Date: 2013-07-29 Impact factor: 3.411